1. Geyelin, H (1921) Fasting as a method for treating epilepsy. Med Rec 99, 1037–1039.
2. Martin, K, Jackson, CF, Levy, RG, et al. (2016) Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev, issue 2, CD001903.
3. McDonald, TJW & Cervenka, MC (2017) Ketogenic diets for adults with highly refractory epilepsy. Epilepsy Curr 17, 346–350.
4. Potschka, H, Fischer, A, von Rüden, EL, et al. (2013) Canine epilepsy as a translational model? Epilepsia 54, 571–579.
5. Martlé, V, Van Ham, L, Raedt, R, et al. (2014) Non-pharmacological treatment options for refractory epilepsy: an overview of human treatment modalities and their potential utility in dogs. Vet J 199, 332–339.
6. Patterson, EE (2014) Canine epilepsy: an underutilized model. ILAR J 55, 182–186.
7. Law, TH, Davies, ESS, Pan, Y, et al. (2015) A randomised trial of a medium-chain TAG diet as treatment for dogs with idiopathic epilepsy. Br J Nutr 114, 1438–1447.
8. Wlaź, P, Socała, K, Nieoczym, D, et al. (2015) Acute anticonvulsant effects of capric acid in seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 57, 110–116.
9. Chang, P, Terbach, N, Plant, N, et al. (2013) Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69, 105–114.
10. Packer, RMA, Law, TH, Davies, E, et al. (2016) Effects of a ketogenic diet on ADHD-like behavior in dogs with idiopathic epilepsy. Epilepsy Behav 55, 62–68.
11. Pulsifer, MB, Gordon, JM, Brandt, J, et al. (2001) Effects of ketogenic diet on development and behavior: preliminary report of a prospective study. Dev Med Child Neurol 43, 301–306.
12. Page, KA, Williamson, A, Yu, N, et al. (2009) Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 58, 1237–1244.
13. Fernando, WMADB, Martins, IJ, Goozee, KG, et al. (2015) The role of dietary coconut for the prevention and treatment of Alzheimer’s disease: potential mechanisms of action. Br J Nutr 114, 1–14.
14. Marten, B, Pfeuffer, M & Schrezenmeir, J (2006) Medium-chain triglycerides. Int Dairy J 16, 1374–1382.
15. St-Onge, MP & Jones, PJH (2002) Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. J Nutr 132, 329–332.
16. Augustin, K, Khabbush, A, Williams, S, et al. (2018) Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol 17, 84–93.
17. Chang, P, Augustin, K, Boddum, K, et al. (2016) Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 139, 431–443.
18. Chang, P, Zuckermann, AME, Williams, S, et al. (2015) Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J Pharmacol Exp Ther 352, 43–52.
19. Maciejak, P, Szyndler, J, Turzyńska, D, et al. (2016) Is the interaction between fatty acids and tryptophan responsible for the efficacy of a ketogenic diet in epilepsy? The new hypothesis of action. Neuroscience 313, 130–148.
20. Maciejak, P, Szyndler, J, Turzyńska, D, et al. (2013) The kynurenine pathway: a missing piece in the puzzle of valproate action? Neuroscience 234, 135–145.
21. Maciejak, P, Szyndler, J, Turzyńska, D, et al. (2011) Kynurenic acid: a new effector of valproate action? Pharmacol Rep 6, 1569–1573.
22. Law, T, Volk, H & Bowen, J (2014) Metabolomics: an alternative approach to canine epilepsy. Vet Times 44, 1–11.
23. Nicholson, JK, Lindon, JC & Holmes, E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189.
24. Want, EJ, Wilson, ID, Gika, H, et al. (2010) Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 5, 1005–1018.
25. Isaac, G, Mcdonald, S & Astarita, G (2011) Lipid Separation Using UPLC with Charged Surface Hybrid Technology. Milford, MA: Waters Corp.
26. Want, EJ, Masson, P, Michopoulos, F, et al. (2013) Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc 8, 17–32.
27. Patterson, EE, Munana, KR, Kirk, CA, et al. (2005) Results of a ketogenic food trial for dogs with idiopathic epilepsy. J Vet Intern Med 19, 421.
28. Benjamini, Y & Hochberg, Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289–300.
29. Godzien, J, Ciborowski, M, Martínez-Alcázar, MP, et al. (2015) Rapid and reliable identification of phospholipids for untargeted metabolomics with LC-ESI-QTOF-MS/MS. J Proteome Res 14, 3204–3216.
30. Papamandjaris, AA, Macdougall, DE & Jones, PJH (1998) Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sci 62, 1203–1215.
31. Rioux, V, Daval, S, Guillou, H, et al. (2003) Although it is rapidly metabolized in cultured rat hepatocytes, lauric acid is used for protein acylation. Reprod Nutr Dev 43, 419–430.
32. Dewey, CW (2006) Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 36, 1107–1127.
33. Wanders, RJA, Komen, J & Kemp, S (2011) Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. FEBS J 278, 182–194.
34. Hill, J, Peters, J, Swift, L, et al. (1990) Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. J Lipid Res 31, 407–416.
35. You, YQ, Ling, PR, Qu, JZ, et al. (2008) Effects of medium-chain triglycerides, long-chain triglycerides, or 2-monododecanoin on fatty acid composition in the portal vein, intestinal lymph, and systemic circulation in rats. J Parenter Enter Nutr 32, 169–175.
36. Vlaeminck, B, Fievez, V, Cabrita, ARJ, et al. (2006) Factors affecting odd- and branched-chain fatty acids in milk: a review. Anim Feed Sci Technol 131, 389–417.
37. Jenkins, BJ, Seyssel, K, Chiu, S, et al. (2017) Odd chain fatty acids; new insights of the relationship between the gut microbiota, dietary intake, biosynthesis and glucose intolerance. Sci Rep 7, 44845.
38. Borges, K & Sonnewald, U (2012) Triheptanoin–a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment? Epilepsy Res 100, 239–244.
39. Tan, KN, Simmons, D, Carrasco-Pozo, C, et al. (2018) Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration. J Neurochem 4, 431–442.
40. de Almeida Rabello Oliveira, M, da Rocha Ataíde, T, de Oliveira, SL, et al. (2008) Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci Lett 434, 66–70.
41. Marin-Valencia, I, Good, LB, Ma, Q, et al. (2013) Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter i-deficient (G1D) brain. J Cereb Blood Flow Metab 33, 175–182.
42. Willis, S, Stoll, J, Sweetman, L, et al. (2010) Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis 40, 565–572.
43. Thomas, NK, Willis, S, Sweetman, L, et al. (2012) Triheptanoin in acute mouse seizure models. Epilepsy Res 99, 312–317.
44. Kim, TH, Borges, K, Petrou, S, et al. (2013) Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy. Epilepsy Res 103, 101–105.
45. Adanyeguh, IM, Rinaldi, D, Henry, P-G, et al. (2015) Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 84, 490–495.
46. Costa, CCG, De Almeida, IT, Jakobs, C, et al. (1999) Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr Res 46, 440–440.
47. Schooneman, MG, Vaz, FM, Houten, SM, et al. (2013) Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62, 1–8.